A Phase I Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (MAB) in B-Cell Lymphoma Patients with Prior Exposure to Rituximab.

Drug Category: Array
Conference Category: Array
Lead Author: Changchun D, O'Connor O, et al.
Published Date: 30/05/2014
Download Link: /wp-content/uploads/2019/03/ASCO2014-Poster-8524.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top